ES2462553B2 - Composition to improve sexual well-being - Google Patents
Composition to improve sexual well-being Download PDFInfo
- Publication number
- ES2462553B2 ES2462553B2 ES201430039A ES201430039A ES2462553B2 ES 2462553 B2 ES2462553 B2 ES 2462553B2 ES 201430039 A ES201430039 A ES 201430039A ES 201430039 A ES201430039 A ES 201430039A ES 2462553 B2 ES2462553 B2 ES 2462553B2
- Authority
- ES
- Spain
- Prior art keywords
- composition according
- sinensis
- agents
- medicament
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000001568 sexual effect Effects 0.000 title claims abstract description 11
- 230000036642 wellbeing Effects 0.000 title claims abstract description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 14
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 7
- 239000004475 Arginine Substances 0.000 claims abstract description 7
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 7
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 7
- 241000110637 Cuscuta chinensis Species 0.000 claims abstract description 7
- 241001632410 Eleutherococcus senticosus Species 0.000 claims abstract description 7
- 241000893536 Epimedium Species 0.000 claims abstract description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 7
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 7
- 240000004371 Panax ginseng Species 0.000 claims abstract description 7
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 7
- 244000294611 Punica granatum Species 0.000 claims abstract description 7
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 7
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 7
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 7
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 7
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 7
- 241001521901 Tribulus lanuginosus Species 0.000 claims abstract description 7
- 244000250129 Trigonella foenum graecum Species 0.000 claims abstract description 7
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims abstract description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910021538 borax Inorganic materials 0.000 claims abstract description 7
- 229960001948 caffeine Drugs 0.000 claims abstract description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 7
- 235000018905 epimedium Nutrition 0.000 claims abstract description 7
- 235000008434 ginseng Nutrition 0.000 claims abstract description 7
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 7
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 7
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 7
- 229960003080 taurine Drugs 0.000 claims abstract description 7
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims abstract description 7
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- 239000011787 zinc oxide Substances 0.000 claims abstract description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract 2
- 229960003121 arginine Drugs 0.000 claims abstract 2
- 229960001708 magnesium carbonate Drugs 0.000 claims abstract 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960004599 sodium borate Drugs 0.000 claims abstract 2
- 239000011726 vitamin B6 Substances 0.000 claims abstract 2
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract 2
- 229960001296 zinc oxide Drugs 0.000 claims abstract 2
- 235000014692 zinc oxide Nutrition 0.000 claims abstract 2
- 239000007910 chewable tablet Substances 0.000 claims description 9
- 229940068682 chewable tablet Drugs 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 101000988412 Homo sapiens cGMP-specific 3',5'-cyclic phosphodiesterase Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BGOFCVIGEYGEOF-UJPOAAIJSA-N helicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UJPOAAIJSA-N 0.000 description 1
- 229940068628 helicin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- BGOFCVIGEYGEOF-UHFFFAOYSA-N salicylaldehyde beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UHFFFAOYSA-N 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a composición administrada por vía oral para la mejora del bienestar sexual de hombres y mujeres sanos que comprende una cantidad efectiva de Angelica sinensis, Cornus officinalis, Curcuma longa, Epimedium, Lycium barbarum, Punica granatum, Schisandra chinensis, Trigonella foenum-graecum, Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, Cuscuta sinensis, Arginina, Cafeina, Carbonato de magnesio, Taurina, Oxido de zinc, Vitamina B6 y Borato sódico. La presente invención también se refiere al uso de la misma para la preparación de un medicamento para la mejora del bienestar sexual de mujeres y hombres sanos.The present invention relates to orally administered composition for the improvement of the sexual well-being of healthy men and women comprising an effective amount of Angelica sinensis, Cornus officinalis, Curcuma longa, Epimedium, Lycium barbarum, Punica granatum, Schisandra chinensis, Trigonella foenum -graecum, Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, Cuscuta sinensis, Arginine, Caffeine, Magnesium carbonate, Taurine, Zinc oxide, Vitamin B6 and Sodium borate. The present invention also relates to the use thereof for the preparation of a medicament for the improvement of the sexual well-being of healthy women and men.
Description
- Ingredientes Ingredients
- mg mg
- Tribulus terrestris Tribulus Terrestris
- 250-750 mg 250-750 mg
- Arginina Arginine
- 125-1000 mg 125-1000 mg
- Taurina Taurine
- 125-1000 mg 125-1000 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 75-300 mg 75-300 mg
- Epimedium Epimedium
- 75-205 mg 75-205 mg
- Carbonato de magnesio Magnesium carbonate
- 100-200 mg 100-200 mg
- Schisandra sinensis Schisandra sinensis
- 50-150 mg 50-150 mg
- Angelica sinensis Angelica sinensis
- 50-100 mg 50-100 mg
- Lycium barbarum Lycium barbarum
- 30-500 mg 30-500 mg
- Cuscuta sinensis Cuscuta sinensis
- 25-200 mg 25-200 mg
- Punica granatum Punica granatum
- 25-500 mg 25-500 mg
- Rhodiola rosea Rhodiola rosea
- 25-500 mg 25-500 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 25-500 mg 25-500 mg
- Panax ginseng Panax ginseng
- 25-500 mg 25-500 mg
- Borato sódico Sodium borate
- 25-50 mg 25-50 mg
- Curcuma longa Curcuma longa
- 20-100 mg 20-100 mg
- Cornus officinalis Cornus officinalis
- 10-40 mg 10-40 mg
- Cafeína Caffeine
- 10-300mg 10-300mg
- Oxido de Zinc Zinc oxide
- 5-13 mg 5-13 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3-6 mg 3-6 mg
La formulación objeto de la presente invención se administra por vía oral (por ejemplo en forma de comprimidos, granulados, soluciones, etc.). De forma preferida es en forma de comprimido masticable de 2500 mg cada comprimido. De forma preferida, la posología adecuada de la presente formulación es de dos comprimidos al menos tres horas antes de comenzar la actividad. De forma preferida se deben tomar fuera de las comidas para mejorar los resultados. The formulation object of the present invention is administered orally (for example in the form of tablets, granules, solutions, etc.). Preferably, it is in the form of a chewable tablet of 2500 mg each tablet. Preferably, the appropriate dosage of the present formulation is two tablets at least three hours before starting the activity. Preferably, they should be taken outside of meals to improve results.
Según otro aspecto, la composición objeto de la presente invención adicionalmente comprende excipientes, tales como agentes hidratantes, agentes antioxidantes, agentes emulgentes, agentes estabilizantes, agentes emolientes y agentes antimicrobianos. According to another aspect, the composition object of the present invention additionally comprises excipients, such as moisturizing agents, antioxidant agents, emulsifying agents, stabilizing agents, emollient agents and antimicrobial agents.
Según otro aspecto la composición está formulada como comprimido masticable. According to another aspect, the composition is formulated as a chewable tablet.
Una composición preferida de la siguiente invención comprende al menos los siguientes elementos en las siguientes cantidades: A preferred composition of the following invention comprises at least the following elements in the following amounts:
5 5
- Ingredientes Ingredients
- mg/composición mg / composition
- Tribulus terrestris Tribulus Terrestris
- 500 mg 500 mg
- Arginina Arginine
- 250,00 mg 250.00 mg
- Taurina Taurine
- 250,00 mg 250.00 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 150,00 mg 150.00 mg
- Epimedium Epimedium
- 125,00 mg 125.00 mg
- Carbonato de magnesio Magnesium carbonate
- 125,00 mg 125.00 mg
- Schisandra sinensis Schisandra sinensis
- 100,00 mg 100.00 mg
- Angelica sinensis Angelica sinensis
- 75,00 mg 75.00 mg
- Lycium barbarum Lycium barbarum
- 60,00 mg 60.00 mg
- Cuscuta sinensis Cuscuta sinensis
- 50,00 mg 50.00 mg
- Punica granatum Punica granatum
- 50,00 mg 50.00 mg
- Rhodiola rosea Rhodiola rosea
- 50,00 mg 50.00 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 50,00 mg 50.00 mg
- Panax ginseng Panax ginseng
- 50,00 mg 50.00 mg
- Borato sódico Sodium borate
- 44,10 mg 44.10 mg
- Curcuma longa Curcuma longa
- 32,50 mg 32.50 mg
- Cornus officinalis Cornus officinalis
- 20,00 mg 20.00 mg
- Cafeína Caffeine
- 15,00 mg 15.00 mg
- Oxido de zinc Zinc oxide
- 6,25 mg 6.25 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3,00 mg 3.00 mg
- Excipientes Excipients
- 491,15 mg 491.15 mg
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento para aumentar el bienestar sexual de hombres y mujeres sanos. According to another aspect, the present invention relates to the use of the aforementioned composition for the preparation of a medicament to increase the sexual well-being of healthy men and women.
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento para el tratamiento de la disfunción eréctil. In accordance with another aspect the present invention relates to the use of the aforementioned composition for the preparation of a medicament for the treatment of erectile dysfunction.
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento en forma de comprimido masticable. De forma preferida el medicamento está en forma de comprimido masticable de 2500 mg. In accordance with another aspect the present invention relates to the use of the aforementioned composition for the preparation of a medicament in the form of a chewable tablet. Preferably, the medicament is in the form of a chewable tablet of 2500 mg.
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento administrado en pautas de posología de dos comprimidos por vía oral al menos tres horas antes del acto sexual. According to another aspect, the present invention relates to the use of the aforementioned composition for the preparation of a medicament administered in dosing guidelines of two tablets orally at least three hours before sexual intercourse.
EJEMPLOS DE REALIZACIÓN: EXAMPLES OF REALIZATION:
Los siguientes ejemplos específicos que se proporcionan aquí sirven para ilustrar la naturaleza de la presente invención. Estos ejemplos se incluyen solamente con fines ilustrativos y no han de ser interpretados como limitaciones a la invención que aquí se reivindica. The following specific examples provided herein serve to illustrate the nature of the present invention. These examples are included for illustrative purposes only and should not be construed as limitations on the invention claimed herein.
Ejemplo 1: Evaluación de la actividad farmacológica para hombres y mujeres Example 1: Evaluation of pharmacological activity for men and women
Mediante un proceso de mezclado, estabilización y compresión se obtiene el comprimido masticable objeto de la presente invención. The chewable tablet object of the present invention is obtained by means of a mixing, stabilization and compression process.
Este comprimido comprende los siguientes elementos: This tablet comprises the following elements:
6 6
- Ingredientes Ingredients
- mg/composición mg / composition
- Tribulus terrestris Tribulus Terrestris
- 500 mg 500 mg
- Arginina Arginine
- 250,00 mg 250.00 mg
- Taurina Taurine
- 250,00 mg 250.00 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 150,00 mg 150.00 mg
- Epimedium Epimedium
- 125,00 mg 125.00 mg
- Carbonato de magnesio Magnesium carbonate
- 125,00 mg 125.00 mg
- Schisandra sinensis Schisandra sinensis
- 100,00 mg 100.00 mg
- Angelica sinensis Angelica sinensis
- 75,00 mg 75.00 mg
- Lycium barbarum Lycium barbarum
- 60,00 mg 60.00 mg
- Cuscuta sinensis Cuscuta sinensis
- 50,00 mg 50.00 mg
- Punica granatum Punica granatum
- 50,00 mg 50.00 mg
- Rhodiola rosea Rhodiola rosea
- 50,00 mg 50.00 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 50,00 mg 50.00 mg
- Panax ginseng Panax ginseng
- 50,00 mg 50.00 mg
- Borato sódico Sodium borate
- 44,10 mg 44.10 mg
- Curcuma longa Curcuma longa
- 32,50 mg 32.50 mg
- Cornus officinalis Cornus officinalis
- 20,00 mg 20.00 mg
- Cafeína Caffeine
- 15,00 mg 15.00 mg
- Oxido de zinc Zinc oxide
- 6,25 mg 6.25 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3,00 mg 3.00 mg
- Excipientes Excipients
- 491,15 mg 491.15 mg
Esta composición se administró tres horas antes del acto sexual, tomando dos comprimidos masticables en una población de 10 varones y 10 mujeres. Al cabo de un mes se les facilitó una encuesta para valorar la actividad y satisfacción con el producto y se apreció satisfactoriamente que los resultados fueron claramente positivos en un 100% de los pacientes encuestados. This composition was administered three hours before sexual intercourse, taking two chewable tablets in a population of 10 men and 10 women. After a month they were given a survey to assess the activity and satisfaction with the product and it was satisfactorily appreciated that the results were clearly positive in 100% of the patients surveyed.
Los parámetros más positivamente aceptados por los pacientes fueron: The most positively accepted parameters by the patients were:
- --
- Vitalidad masculina: bienestar de la fisiología masculina para el adecuado funcionamiento a nivel sexual. Male vitality: well-being of male physiology for proper functioning at the sexual level.
- --
- Actividad energizante: aumenta la resistencia y potencia masculina, el deseo sexual y la claridad mental. Energizing activity: increases male endurance and potency, sexual desire and mental clarity.
- --
- Factor psicológico: mejora la superación de situaciones de estrés y desgano físico, específicamente en el plano Psychological factor: improves the overcoming of situations of stress and physical reluctance, specifically in the plane
- sexual. sexual.
- --
- Calidad de la función sexual. Quality of sexual function.
- --
- Aumento del deseo sexual en mujeres. Increased sexual desire in women.
Ejemplo 2: Actividad Biológica sobre la inhibición de la enzima PDE5A Example 2: Biological Activity on the inhibition of the PDE5A enzyme
Parte del proceso fisiológico de la erección incluye al sistema nervioso parasimpático causando la liberación de óxido nítrico (NO) en el cuerpo cavernoso del pene. El NO se une a los receptores de la enzima guanilato ciclasa, lo que deriva en niveles aumentados de guanosín monofosfato cíclico (GMPc), llevando a una relajación del músculo liso del cuerpo cavernoso, mediante vasodilatación de las arterias helicinas del interior del pene. La vasodilatación incrementa el flujo de sangre en el interior del pene, causando así la erección. Robert F. Furchgott ganó el Premio Nobel de Fisiología y Medicina en 1998 por el descubrimiento y el análisis del factor de relajación derivado del endotelio (EDRF en siglas en inglés: endothelium-derived relaxing factor), que posteriormente fue identificado como óxido nítrico o algún otro compuesto relacionado muy cercano. Part of the physiological process of erection includes the parasympathetic nervous system causing the release of nitric oxide (NO) in the cavernous body of the penis. NO binds to the guanylate cyclase enzyme receptors, resulting in increased levels of cyclic guanosine monophosphate (cGMP), leading to a relaxation of the smooth muscle of the cavernous body, by vasodilation of the helicin arteries inside the penis. Vasodilation increases the flow of blood inside the penis, thus causing erection. Robert F. Furchgott won the Nobel Prize in Physiology and Medicine in 1998 for the discovery and analysis of the endothelium-derived relaxation factor (EDRF), which was subsequently identified as nitric oxide or some Another related compound very close.
Hay compuestos conocidos en el estado de técnica como el sildenafilo, cuyo mecanismo de acción consiste en la inhibición específica de la fosfodiesterasa tipo 5 (PDE5) que es responsable de la degradación del GMPc en el cuerpo cavernoso. La estructura molecular del sildenafilo es similar a la del GMPc compitiendo por la unión de éste a PDE5. El There are compounds known in the state of the art as sildenafil, whose mechanism of action consists in the specific inhibition of phosphodiesterase type 5 (PDE5) that is responsible for the degradation of cGMP in the corpora cavernosa. The molecular structure of sildenafil is similar to that of cGMP competing for its binding to PDE5. He
7 7
Claims (10)
- Ingredientes Ingredients
- miligramos milligrams
- Tribulus terrestris Tribulus Terrestris
- 250-750 mg 250-750 mg
- Arginina Arginine
- 125-1000 mg 125-1000 mg
- Taurina Taurine
- 125-1000 mg 125-1000 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 75-300 mg 75-300 mg
- Epimedium Epimedium
- 75-205 mg 75-205 mg
- Carbonato de magnesio Magnesium carbonate
- 100-200 mg 100-200 mg
- Schisandra sinensis Schisandra sinensis
- 50-150 mg 50-150 mg
- Angelica sinensis Angelica sinensis
- 50-100 mg 50-100 mg
- Lycium barbarum Lycium barbarum
- 30-500 mg 30-500 mg
- Cuscuta sinensis Cuscuta sinensis
- 25-200 mg 25-200 mg
- Punica granatum Punica granatum
- 25-500 mg 25-500 mg
- Rhodiola rosea Rhodiola rosea
- 25-500 mg 25-500 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 25-500 mg 25-500 mg
- Panax ginseng Panax ginseng
- 25-500 mg 25-500 mg
- Borato sódico Sodium borate
- 25-50 mg 25-50 mg
- Curcuma longa Curcuma longa
- 20-100 mg 20-100 mg
- Cornus officinalis Cornus officinalis
- 10-40 mg 10-40 mg
- Cafeína Caffeine
- 10-300mg 10-300mg
- Oxido de zinc Zinc oxide
- 5-13 mg 5-13 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3-6 mg 3-6 mg
- Ingredientes Ingredients
- miligramos milligrams
- Tribulus terrestris Tribulus Terrestris
- 500 mg 500 mg
- Arginina Arginine
- 250,00 mg 250.00 mg
- Taurina Taurine
- 250,00 mg 250.00 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 150,00 mg 150.00 mg
- Epimedium Epimedium
- 125,00 mg 125.00 mg
- Carbonato de magnesio Magnesium carbonate
- 125,00 mg 125.00 mg
- Schisandra sinensis Schisandra sinensis
- 100,00 mg 100.00 mg
- Angelica sinensis Angelica sinensis
- 75,00 mg 75.00 mg
- Lycium barbarum Lycium barbarum
- 60,00 mg 60.00 mg
- Cuscuta sinensis Cuscuta sinensis
- 50,00 mg 50.00 mg
- Punica granatum Punica granatum
- 50,00 mg 50.00 mg
- Rhodiola rosea Rhodiola rosea
- 50,00 mg 50.00 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 50,00 mg 50.00 mg
- Panax ginseng Panax ginseng
- 50,00 mg 50.00 mg
- Borato sódico Sodium borate
- 44,10 mg 44.10 mg
- Curcuma longa Curcuma longa
- 32,50 mg 32.50 mg
- Cornus officinalis Cornus officinalis
- 20,00 mg 20.00 mg
- Cafeína Caffeine
- 15,00 mg 15.00 mg
- Oxido de zinc Zinc oxide
- 6,25 mg 6.25 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3,00 mg 3.00 mg
- Excipientes Excipients
- 491,15 mg 491.15 mg
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430039A ES2462553B2 (en) | 2014-01-16 | 2014-01-16 | Composition to improve sexual well-being |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430039A ES2462553B2 (en) | 2014-01-16 | 2014-01-16 | Composition to improve sexual well-being |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2462553A1 ES2462553A1 (en) | 2014-05-23 |
| ES2462553B2 true ES2462553B2 (en) | 2014-11-05 |
Family
ID=50732646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201430039A Active ES2462553B2 (en) | 2014-01-16 | 2014-01-16 | Composition to improve sexual well-being |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2462553B2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906229A (en) * | 2015-06-08 | 2015-09-16 | 山东大学齐鲁医院 | Traditional Chinese medicine gel preparation for treating cervicitis |
| CN104887809A (en) * | 2015-06-15 | 2015-09-09 | 平阴县中医医院 | Medicine for treating gynecologic inflammation and preparation method thereof |
| CN107890473A (en) * | 2017-11-27 | 2018-04-10 | 中国科学院兰州化学物理研究所 | A kind of composition with fatigue-relieving and Yang strengthening function |
| EP3610882A1 (en) * | 2018-06-11 | 2020-02-19 | Mohammad S. Majid | Herbal combination product |
| CN108653644A (en) * | 2018-07-20 | 2018-10-16 | 成都润馨堂药业有限公司 | A kind of pharmaceutical composition of warming kidney and enhancing yang and its preparation method and application |
| US10967024B2 (en) * | 2018-09-26 | 2021-04-06 | Aretha Duncan | Synergistic herbal stimulant compositions |
| WO2022175981A1 (en) * | 2021-02-18 | 2022-08-25 | Sipwise Beverages Pvt. Ltd | A synergistic herbal composition for improving sexual wellness in females |
| WO2022175980A1 (en) * | 2021-02-18 | 2022-08-25 | Sipwise Beverages Pvt. Ltd | A synergistic herbal composition for improving male sexual wellness |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4168811B2 (en) * | 2003-04-07 | 2008-10-22 | 大正製薬株式会社 | Beverage composition |
| WO2006021930A2 (en) * | 2004-08-25 | 2006-03-02 | Femi-X A/S | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
| DE102006006532B4 (en) * | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmaceutical preparation |
| US7658956B2 (en) * | 2006-07-28 | 2010-02-09 | Jose Angel Olalde Rangel | Erectile dysfunction phyto-nutraceutical synergistic composition |
| US20090092687A1 (en) * | 2007-10-03 | 2009-04-09 | Stein Daniel S | Prhormone composition and method of use thereof |
| CN101317940A (en) * | 2008-07-14 | 2008-12-10 | 王跃进 | Traditional Chinese medicine capsule for increasing spermatozoon |
| ES2386859B1 (en) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | NATURAL COMPOSITION TO INCREASE VIGOR. |
| CN102949521A (en) * | 2012-11-23 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Pure traditional Chinese medicinal health care product used for relieving physical fatigue and preparation method thereof |
-
2014
- 2014-01-16 ES ES201430039A patent/ES2462553B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2462553A1 (en) | 2014-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2462553B2 (en) | Composition to improve sexual well-being | |
| Seigers et al. | Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats | |
| Khan et al. | Anti-hyperalgesic and anti-allodynic activities of capillarisin via suppression of inflammatory signaling in animal model | |
| Cole et al. | Arum Palaestinum with isovanillin, linolenic acid and β-sitosterol inhibits prostate cancer spheroids and reduces the growth rate of prostate tumors in mice | |
| AR084816A1 (en) | METHODS AND MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| ES2259144T3 (en) | USEFUL FORMULATIONS IN THE TREATMENT OF MALE AND FEMALE IMPOTENCE. | |
| Sahoo et al. | Aphrodisiac activity of polyherbal formulation in experimental models on male rats | |
| ES2804324T3 (en) | Compositions containing extracts of Curcuma longa and Echinacea angustifolia that are useful for reducing peripheral inflammation and pain | |
| CL2020000625A1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein. | |
| PT1658854E (en) | Formulations useful in the treatment of male and female impotence | |
| Guler et al. | Synergic and comparative effect of 5-fluorouracil and leucoverin on breast and colon cancer cells through TRPM2 channels | |
| Kushwaha et al. | Biochemical assessment of nephroprotective and nephrocurative activity of Withania somnifera on gentamicin-induced nephrotoxicity in experimental rats | |
| JP2005082523A5 (en) | ||
| RU2015145451A (en) | PRODUCTS FOR LOCAL USE CONTAINING HYALURONIC ACID, VERBASCOZIDE AND GLYCEROPHOSPHOINOSITOL | |
| Ubaid et al. | Protective effect of cinnamon oil against ciprofloxacin toxicity on liver and kidney of male Wistar rats | |
| Praptiwi et al. | Evaluation of aphrodisiac activity of yellow Ginseng (Rennelia elliptica Korth.) root ethanol extract in male ddy mice (mus musculus) | |
| Roesler et al. | Is it time to conclude that NMDA antagonists have failed? | |
| IT201800003814A1 (en) | FORMULATION BASED ON COFFEE POWDER | |
| BR112019024373A2 (en) | method to improve physical performance and treatment method to improve physical or mental performance | |
| de Souza et al. | Commentary: Adenosine A2A receptor blockade prevents rotenone-induced motor impairment in a rat model of parkinsonism | |
| ES2917975T3 (en) | Food supplements for use in the prophylaxis and treatment of migraine | |
| RU2010122438A (en) | ANTIVIRAL AGENT FOR PREVENTION AND TREATMENT OF tick-borne encephalitis | |
| US20110034403A1 (en) | use of ginsenoside rg1, its metabolites ginsenoside rh1 and/or ppt | |
| Cavallini et al. | Phytotherapy of Male Hypoactive Sexual Desire of Psychogenic Origin | |
| Sanjeewani et al. | Determination Of Hypoglycemic Activity of The Leaves Of Adenanthera Pavonina (Madatiya) An Animal Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2462553 Country of ref document: ES Kind code of ref document: B2 Effective date: 20141105 |